Sumitomo Licenses an Antitumor Drug, Amrubicin Hydrochloride, to Conforma
On June 30, Sumitomo Pharmaceuticals, Co., Ltd. (Osaka, Japan) announced that the company has signed a license agreement of Amrubicin Hydrochloride with Conforma Therapeutics Corporation (San Diego, California, USA). Pursuant to this agreement, Sumitomo granted Conforma an exclusive license for development and marketing of Amrubicin Hydrochloride in North America and Europe. Financial terms were not disclosed.
Amrubicin Hydrochloride is the totally synthesized anthracycline drug and has the potential to be a therapeutic option for the first line treatment of lung cancer or other anthracycline-sensitive tumor because of its efficacy and safety. Sumitomo developed and launched this product for small cell lung cancer and non-small cell lung cancer in December 2002 in Japan. The additional development for Non Hodgkin's Lymphoma is underway in Japan.
Sumitomo intended to develop and commercialize this product worldwide as early as possible by itself or a partnership with other parties to contribute to more patients suffering from cancer. Through introducing the clinical data generated in Japan at various international conference such as American Society of Clinical Oncology (ASCO), many overseas oncologists and pharmaceutical companies showed strong interested in this product. It has decided to collaborate with Conforma to accelerate the development and marketing approvals for early commercialization of this product in the North America and Europe.
Sumitomo believes that Conforma is the best partner because it has been specialized in development of novel drugs for treatment of cancer.
About Conforma Therapeutics Corporation.
President and CEO Lawrence C. Fritz, Ph.D
Head Office San Diego, CA, USA
Date of Establishment 1999